Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
- 430 Downloads
Alectinib, a central nervous system (CNS)-active ALK inhibitor, has demonstrated efficacy and safety in ALK+ non-small-cell lung cancer that has progressed following crizotinib treatment. Other ALK inhibitors have shown concentration-dependent QTc prolongation and treatment-related bradycardia. Therefore, this analysis evaluated alectinib safety in terms of electrophysiologic parameters.
Intensive triplicate centrally read electrocardiogram (ECG) and matched pharmacokinetic data were collected across two alectinib single-arm trials. Analysis of QTcF included central tendency analysis [mean changes from baseline with one-sided upper 95% confidence intervals (CIs)], categorical analyses, and relationship between change in QTcF and alectinib plasma concentrations. Alectinib effects on other ECG parameters (heart rate, PR interval and QRS duration) were also evaluated.
Alectinib did not cause a clinically relevant change in QTcF. The maximum mean QTcF change from baseline was 5.3 ms observed pre-dose at week 2. The upper one-sided 95% CI was <10 ms at all time points. There was no relevant relationship between change in QTcF and alectinib plasma concentrations. Alectinib treatment resulted in a generally asymptomatic exposure-dependent decrease in mean heart rate of ~11 to 13 beats per minute at week 2. No clinically relevant effects were seen on other ECG parameters. Approximately 5% of patients reported cardiac adverse events of bradycardia or sinus bradycardia; however, these were all grade 1–2.
Alectinib does not prolong the QTc interval or cause changes in cardiac function to a clinically relevant extent, with the exception of a decrease in heart rate which was generally asymptomatic.
KeywordsAlectinib ALK inhibitor NSCLC Cardiac safety ECG data
Third-party medical writing assistance, under the direction of the authors, was provided by Joanna Musgrove, MRes of Gardiner-Caldwell Communications, and was funded by F. Hoffmann-La Roche Ltd.
Compliance with ethical standards
Conflict of interest
All authors are employees of F. Hoffmann-La Roche Ltd. and have stock in F. Hoffmann-La Roche Ltd.
- 3.Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, PROFILE (1014) Investigators (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177CrossRefGoogle Scholar
- 5.Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH, study investigators (2016) Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17:234–242CrossRefPubMedGoogle Scholar
- 6.Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW (2016) Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661–668CrossRefPubMedGoogle Scholar
- 7.International Conference on Harmonization (2005) Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugsGoogle Scholar
- 9.US Food and Drug Administration (2016) Clinical pharmacology and biopharmaceutics review(s) of alectinib. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000PharmR.pdf. Accessed 6 July 2016
- 10.Hsu JC, Carnac R, Henschel V, Bogman K, Martin-Facklam M, Guerini E, Balas B, Hassan Zeaiter A, Phipps A, Morcos PN, Frey N (2016) Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population. J Clin Oncol 34(Suppl; abstr):e20598Google Scholar
- 13.Morcos PN, Cleary Y, Guerini E, Dall G, Bogman K, De Petris L, Viteri S, Bordogna W, Yu L, Martin-Facklam M, Phipps A (2016) Clinical drug–drug interactions (DDIs) through cytochrome P450 3 A (CYP3A) for alectinib, a highly selective ALK inhibitor. Clin Pharmacol Ther 99(abstr PI-119):S62Google Scholar
- 14.Gadgeel S, Gandhi L, Riely G, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–1128CrossRefPubMedGoogle Scholar
- 16.US Food and Drug Administration (2016) Xalkori prescribing information. http://labeling.pfizer.com/showlabeling.aspx?id=676. Accessed 26 July 2016
- 17.US Food and Drug Administration (2015) Zykadia prescribing information. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/zykadia.pdf. Accessed 26 July 2016
- 20.US Food and Drug Administration (2014) Clinical/statistical review of ceritinib. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000MedR.pdf. Accessed 26 Aug 2016